Nymox Pharmaceutical Corporation
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of products for the aging population in Canada, the United States, and Europe. Its lead drug candidate is Fexapotide Triflutate (NX-1207) for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as hepatocellular carcinoma. The company also offers NicAle… Read more
Nymox Pharmaceutical Corporation (NYMXF) - Net Assets
Latest net assets as of December 2023: $-3.17 Million USD
Based on the latest financial reports, Nymox Pharmaceutical Corporation (NYMXF) has net assets worth $-3.17 Million USD as of December 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($627.00K) and total liabilities ($3.80 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-3.17 Million |
| % of Total Assets | -506.06% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 291.63 |
Nymox Pharmaceutical Corporation - Net Assets Trend (2019–2023)
This chart illustrates how Nymox Pharmaceutical Corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Nymox Pharmaceutical Corporation (2019–2023)
The table below shows the annual net assets of Nymox Pharmaceutical Corporation from 2019 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $-3.17 Million | -558.30% |
| 2022-12-31 | $-482.00K | -680.72% |
| 2021-12-31 | $83.00K | -96.96% |
| 2020-12-31 | $2.73 Million | -32.28% |
| 2019-12-31 | $4.04 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Nymox Pharmaceutical Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3969500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $173.82 Million | % |
| Other Comprehensive Income | $3.21 Million | % |
| Other Components | $27.78 Million | % |
| Total Equity | $-3.17 Million | 100.00% |
Nymox Pharmaceutical Corporation Competitors by Market Cap
The table below lists competitors of Nymox Pharmaceutical Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Yoshiharu Global Co.
NASDAQ:YOSH
|
$5.30 Million |
|
Enthusiast Gaming Holdings Inc.
PINK:EGLXF
|
$5.30 Million |
|
Sietel Ltd
AU:SSL
|
$5.30 Million |
|
Montebalito S.A.
MC:MTB
|
$5.30 Million |
|
Scandium Interna
TO:SCY
|
$5.30 Million |
|
KCI SA
WAR:KCI
|
$5.30 Million |
|
TGS Esports Inc
V:TGS
|
$5.29 Million |
|
SUPERNOVA METALS CORP.
F:A1S
|
$5.29 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nymox Pharmaceutical Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from -482,000 to -3,173,000, a change of -2,691,000.
- Net loss of 8,844,000 reduced equity.
- New share issuances of 1,150,000 increased equity.
- Other comprehensive income increased equity by 3,209,000.
- Other factors increased equity by 1,794,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-8.84 Million | -278.73% |
| Share Issuances | $1.15 Million | +36.24% |
| Other Comprehensive Income | $3.21 Million | +101.13% |
| Other Changes | $1.79 Million | +56.54% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Nymox Pharmaceutical Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.06 | $0.10 | x |
| 2020-12-31 | $0.04 | $0.10 | x |
| 2021-12-31 | $0.00 | $0.10 | x |
| 2022-12-31 | $-0.01 | $0.10 | x |
| 2023-12-31 | $-0.03 | $0.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nymox Pharmaceutical Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-3172.04%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -326.03% | -11346.55% | 0.02x | 1.51x | $-13.57 Million |
| 2020 | -429.33% | -234760.00% | 0.00x | 1.80x | $-12.01 Million |
| 2021 | -15104.82% | 0.00% | 0.00x | 24.48x | $-12.55 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.53 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.53 Million |
Industry Comparison
This section compares Nymox Pharmaceutical Corporation's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nymox Pharmaceutical Corporation (NYMXF) | $-3.17 Million | -326.03% | N/A | $5.30 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |